

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar International Holdings Company Limited

巨星國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

HIGH CONCENTRATION OF SHAREHOLDING

This announcement is made by the Company at the request of the Stock Exchange in respect of the concentration of the shareholding of the Company in the hands of a limited number of shareholders as at 27 January 2015.

In view of the high concentration of shareholding in a small number of shareholders, shareholders and prospective investors should be aware that the price of the shares of the Company (“Shares”) could fluctuate substantially even with a small number of shares traded, and should exercise extreme caution when dealing in the Shares.

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) in respect of the concentration of the shareholding of Yestar International Holdings Company Limited (the “Company”) in the hands of a limited number of shareholders of the Company (the “Shareholders”) as at 27 January 2015.

HIGH CONCENTRATION OF SHAREHOLDING

The Company noted that an announcement has been published by the Securities and Futures Commission (the “SFC”) on 11 February 2015 (the “SFC Announcement”).

As disclosed in the SFC announcement, the SFC has recently completed an enquiry into the shareholding of the Company. The SFC’s findings suggested that as at 27 January 2015, 16

shareholders held an aggregate of 392,171,588 Shares, representing 21.00% of the issued Shares. Such shareholding, together with 1,327,185,000 Shares (representing 71.07% of the issued Shares) held by 4 substantial shareholders of the Company, represented 92.07% of the issued Shares as at 27 January 2015. Therefore only 148,143,412 Shares (representing 7.93% of the issued Shares) were held by other shareholders.

The information above is extracted from the SFC Announcement and the Company has not independently verified such information. Please also refer to the SFC Announcement for other information.

As set out in the SFC Announcement, the shareholdings structure of the Company as at 27 January 2015 was as follows:-

	Number of Shares held (Shares)	% of total number of issued Shares (%)
Jeane Hartono (<i>Note 1</i>)	676,890,000	36.25
James Hartono (<i>Note 1</i>)	265,410,000	14.21
Rico Hartono (<i>Note 1</i>)	265,410,000	14.21
Chen Chen Irene Hartono (<i>Note 1</i>)	119,475,000	6.40
A group of 16 shareholders	392,171,588	21.00
Other shareholders	148,143,412	7.93
Total	<u>1,867,500,000</u>	<u>100.00</u>

Note 1: Ms. Jeane Hartono, Mr. Rico Hartono and Ms. Chen Chen Irene Hartono are all siblings of Mr. James Hartono, the Chairman and Executive Director of the Company.

The Company was listed on the Main Board of the Stock Exchange of Hong Kong Limited on 11 October 2013 by way of global offering of 450,000,000 Shares, representing 25.00% of the issued Shares, at an initial public offer (“IPO”) price of HK\$0.345 per Share (*Note 2*). The share price closed at HK\$0.395 on its first day of listing, 14.49% higher than the IPO price.

Subsequently, the closing price of the Shares increased 554.43% from HK\$0.395 on 11 October 2013 to HK\$2.585 on 17 November 2014 and then decreased to HK\$1.80 on 14 January 2015.

On 15 January 2015, the Company announced a positive profit alert stating that it was expected to record an increase of not less than 40% in its consolidated net profit for the year ended 31 December 2014 as compared with that of the year ended 31 December 2013.

On 26 January 2015, the Company announced that it is in a preliminary stage of considering the feasibility of an acquisition of a company which is principally engaged in the medical in vitro diagnostic industry in the PRC, which is subject to further negotiation and the results of due diligence, which may or may not materialize.

As at 10 February 2015, the Shares closed at HK\$2.43, representing an increase of 35.00% from 14 January 2015 or an increase of 515.19% since its first day of listing.

Note 2: The original IPO price was HK\$1.38. All prices and share quantity above have been adjusted for a 1-to-4 Share subdivision which was effective on 16 December 2014.

PUBLIC FLOAT

Based on the information available and to the best knowledge of the board of Directors after making all reasonable enquiries of its connected persons, the Company confirms that not less than 25% of the Company's issued Shares are in the hands of the public as at 27 January 2015 and the date of this announcement and the Company is able to comply with the public float requirement under the Rules Governing the Listing of Securities on the Stock Exchange.

In view of the high concentration of shareholding in a small number of shareholders, shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of shares traded, and should exercise extreme caution when dealing in the Shares.

By Order of the Board
Yestar International Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

Hong Kong, 11 February 2015

As at the date of this announcement, the executive Directors of the Company are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong, Ms. Zhang Qi and Ms. Heng Yinmei; the independent non-executive Directors of the Company are Dr. Hu Yiming, Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.